Download PDF
Horm Metab Res 2004; 36(11/12): 846-851
DOI: 10.1055/s-2004-826174
Review
© Georg Thieme Verlag KG Stuttgart · New York

Gastrointestinal Hormones and Regulation of Food Intake

W.  S.  Dhillo1 , S.  R.  Bloom1
  • 1 Department of Metabolic Medicine, Imperial College Faculty of Medicine, Hammersmith Hospital, London, United Kingdom
Further Information

Publication History

Received 4 August 2004

Accepted after revision 23 August 2004

Publication Date:
18 January 2005 (online)

Also available at
    Permissions and Reprints

Abstract

Obesity has been described as the greatest current threat to human health. In order to design drugs to target obesity, it is essential to understand its physiology and pathophysiology. Several peptides synthesised in the gastrointestinal tract which affect food intake have been identified including ghrelin, cholecystokinin (CCK), glucagon-like peptide-1 (7 - 36) amide (GLP-1), oxyntomodulin, peptide YY (PYY) and pancreatic polypeptide (PP). These peptides represent potential targets for the design of anti-obesity drugs. In this article we review recent advances in our understanding of food intake by these gastrointestinal hormones.

Key words

Ghrelin - Cholecystokinin (cck) - Glucagon-like peptide-1 (7 - 36) amide (glp-1) - Oxyntomodulin - Peptide YY (pyy) - Pancreatic polypeptide (pp) - Obesity

References

  • 1 Royal College of Physicians, Faculty of Public Health, Royal College of Paediatrics and Child Health Report .Storing Up Problems: The medical case for a slimmer nation. Report of a working party. London; 2004
    Google Scholar
  • 2 Cone R D, Cowley M A, Butler A A, Fan W, Marks D L, Low M J. The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis.  Int J Obes Relat Metab Disord. 2001;  25 Suppl 5 S63-S67
    CrossrefPubMedGoogle Scholar
  • 3 Wren A M, Small C J, Abbott C R, Dhillo W S, Seal L J, Cohen M A, Batterham R L, Taheri S, Stanley S A, Ghatei M A, Bloom S R. Ghrelin causes hyperphagia and obesity in rats.  Diabetes. 2001;  50 2540-2547
    CrossrefPubMedGoogle Scholar
  • 4 Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach.  Nature. 1999;  402 656-660
    CrossrefPubMedGoogle Scholar
  • 5 Petersenn S. Structure and regulation of the growth hormone secretagogue receptor.  Minerva Endocrinol. 2002;  27 243-256
    PubMedGoogle Scholar
  • 6 Tschop M, Smiley D L, Heiman M L. Ghrelin induces adiposity in rodents.  Nature. 2000;  407 908-913
    CrossrefPubMedGoogle Scholar
  • 7 Ruter J, Kobelt P, Tebbe J J, Avsar Y, Veh R, Wang L, Klapp B F, Wiedenmann B, Tache Y, Monnikes H. Intraperitoneal injection of ghrelin induces Fos expression in the paraventricular nucleus of the hypothalamus in rats.  Brain Res. 2003;  991 26-33
    CrossrefPubMedGoogle Scholar
  • 8 Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S. A role for ghrelin in the central regulation of feeding.  Nature. 2001;  409 194-198
    CrossrefPubMedGoogle Scholar
  • 9 Chen H Y, Trumbauer M E, Chen A S, Weingarth D T, Adams J R, Frazier E G, Shen Z, Marsh D J, Feighner S D, Guan X M, Ye Z, Nargund R P, Smith R G, Van der Ploeg L H, Howard A D, MacNeil D J, Qian S. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein.  Endocrinology. 2004;  145 2607-2612
    CrossrefPubMedGoogle Scholar
  • 10 Andersson U, Filipsson K, Abbott C R, Woods A, Smith K, Bloom S R, Carling D, Small C J. AMP-activated protein kinase plays a role in the control of food intake.  J Biol Chem. 2004;  279 12 005-12 008
    PubMedGoogle Scholar
  • 11 Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, Matsuo H, Kangawa K, Nakazato M. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats.  Gastroenterology. 2002;  123 1120-1128
    CrossrefPubMedGoogle Scholar
  • 12 Sun Y, Ahmed S, Smith R G. Deletion of ghrelin impairs neither growth nor appetite.  Mol Cell Biol. 2003;  23 7973-7981
    CrossrefPubMedGoogle Scholar
  • 13 Sun Y, Wang P, Zheng H, Smith R G. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor.  Proc Natl Acad Sci U S A. 2004;  101 4679-4684
    CrossrefPubMedGoogle Scholar
  • 14 Wortley K E, Anderson K D, Garcia K, Murray J D, Malinova L, Liu R, Moncrieffe M, Thabet K, Cox H J, Yancopoulos G D, Wiegand S J, Sleeman M W. Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference.  Proc Natl Acad Sci U S A. 2004;  101 8227-8232
    CrossrefPubMedGoogle Scholar
  • 15 Tang-Christensen M, Vrang N, Ortmann S, Bidlingmaier M, Horvath T, Tschop M. Central administration of Ghrelin and Agouti-related Protein (AGRP (83 - 132)) increases food intake and decreases spontaneous locomotor activity in rats.  Endocrinology. 2004;  in press
    PubMedGoogle Scholar
  • 16 Wren A M, Seal L J, Cohen M A, Brynes A E, Frost G S, Murphy K G, Dhillo W S, Ghatei M A, Bloom S R. Ghrelin enhances appetite and increases food intake in humans.  J Clin Endocrinol Metab. 2001;  86 5992
    CrossrefPubMedGoogle Scholar
  • 17 Neary N M, Small C J, Wren A M, Lee J L, Druce M R, Palmieri C, Frost G S, Ghatei M A, Coombes R C, Bloom S R. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial.  J Clin Endocrinol Metab. 2004;  89 2832-2836
    CrossrefPubMedGoogle Scholar
  • 18 Cummings D E, Purnell J Q, Frayo R S, Schmidova K, Wisse B E, Weigle D S. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans.  Diabetes. 2001;  50 1714-1719
    CrossrefPubMedGoogle Scholar
  • 19 Callahan H S, Cummings D E, Pepe M S, Breen P A, Matthys C C, Weigle D S. Postprandial suppression of plasma ghrelin level is proportional to ingested caloric load but does not predict intermeal interval in humans.  J Clin Endocrinol Metab. 2004;  89 1319-1324
    CrossrefPubMedGoogle Scholar
  • 20 Cummings D E, Weigle D S, Frayo R S, Breen P A, Ma M K, Dellinger E P, Purnell J Q. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery.  N Engl J Med. 2002;  346 1623-1630
    CrossrefPubMedGoogle Scholar
  • 21 Yildiz B O, Suchard M A, Wong M L, McCann S M, Licinio J. Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity.  Proc Natl Acad Sci U S A. 2004;  in press
    PubMedGoogle Scholar
  • 22 Gibbs J, Young R C, Smith G P. Cholecystokinin decreases food intake in rats.  J Comp Physiol Psychol. 1973;  84 488-495
    CrossrefPubMedGoogle Scholar
  • 23 Kissileff H R, Pi-Sunyer F X, Thornton J, Smith G P. C-terminal octapeptide of cholecystokinin decreases food intake in man.  Am J Clin Nutr. 1981;  34 154-160
    PubMedGoogle Scholar
  • 24 Muurahainen N, Kissileff H R, Derogatis A J, Pi-Sunyer F X. Effects of cholecystokinin-octapeptide (CCK-8) on food intake and gastric emptying in man.  Physiol Behav. 1988;  44 645-649
    CrossrefPubMedGoogle Scholar
  • 25 Moran T H, Schwartz G J. Neurobiology of cholecystokinin.  Crit Rev Neurobiol. 1994;  9 1-28
    PubMedGoogle Scholar
  • 26 Smith G P, Jerome C, Cushin B J, Eterno R, Simansky K J. Abdominal vagotomy blocks the satiety effect of cholecystokinin in the rat.  Science. 1981;  213 1036-1037
    PubMedGoogle Scholar
  • 27 Wang L, Martinez V, Barrachina M D, Tache Y. Fos expression in the brain induced by peripheral injection of CCK or leptin plus CCK in fasted lean mice.  Brain Res. 1998;  791 157-166
    CrossrefPubMedGoogle Scholar
  • 28 Fan W, Boston B A, Kesterson R A, Hruby V J, Cone R D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome.  Nature. 1997;  385 165-168
    CrossrefPubMedGoogle Scholar
  • 29 Fan W, Ellacott K L, Halatchev I G, Takahashi K, Yu P, Cone R D. Cholecystokinin-mediated suppression of feeding involves the brainstem melanocortin system.  Nat Neurosci. 2004;  7 335-336
    CrossrefPubMedGoogle Scholar
  • 30 Beglinger C, Degen L, Matzinger D, D’Amato M, Drewe J. Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans.  Am J Physiol Regul Integr Comp Physiol. 2001;  280 R1149-R1154
    PubMedGoogle Scholar
  • 31 Moran T H, Katz L F, Plata-Salaman C R, Schwartz G J. Disordered food intake and obesity in rats lacking cholecystokinin A receptors.  Am J Physiol. 1998;  274 R618-R625
    PubMedGoogle Scholar
  • 32 Kopin A S, Mathes W F, McBride E W, Nguyen M, Al-Haider W, Schmitz F, Bonner-Weir S, Kanarek R, Beinborn M. The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight.  J Clin Invest. 1999;  103 383-391
    PubMedGoogle Scholar
  • 33 West D B, Fey D, Woods S C. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats.  Am J Physiol. 1984;  246 R776-R787
    PubMedGoogle Scholar
  • 34 Crawley J N, Beinfeld M C. Rapid development of tolerance to the behavioural actions of cholecystokinin.  Nature. 1983;  302 703-706
    CrossrefPubMedGoogle Scholar
  • 35 Leach S D, Modlin I M, Scheele G A, Gorelick F S. Intracellular activation of digestive zymogens in rat pancreatic acini. Stimulation by high doses of cholecystokinin.  J Clin Invest. 1991;  87 362-366
    PubMedGoogle Scholar
  • 36 Andren-Sandberg A, Hoem D, Backman P L. Other risk factors for pancreatic cancer: hormonal aspects.  Ann Oncol. 1999;  10 Suppl 4 131-135
    CrossrefPubMedGoogle Scholar
  • 37 Turton M D, O’Shea D, Gunn I, Beak S A, Edwards C M, Meeran K, Choi S J, Taylor G M, Heath M M, Lambert P D, Wilding J P, Smith D M, Ghatei M A, Herbert J, Bloom S R. A role for glucagon-like peptide-1 in the central regulation of feeding.  Nature. 1996;  379 69-72
    CrossrefPubMedGoogle Scholar
  • 38 Meeran K, O’Shea D, Edwards C M, Turton M D, Heath M M, Gunn I, Abusnana S, Rossi M, Small C J, Goldstone A P, Taylor G M, Sunter D, Steere J, Choi S J, Ghatei M A, Bloom S R. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9 - 39) alters body weight in the rat.  Endocrinology. 1999;  140 244-250
    CrossrefPubMedGoogle Scholar
  • 39 Verdich C, Flint A, Gutzwiller J P, Naslund E, Beglinger C, Hellstrom P M, Long S J, Morgan L M, Holst J J, Astrup A. A meta-analysis of the effect of glucagon-like peptide-1(7-36) amide on ad libitum energy intake in humans.  J Clin Endocrinol Metab. 2001;  86 4382-4389
    CrossrefPubMedGoogle Scholar
  • 40 Verdich C, Toubro S, Buemann B, Lysgard M J, Juul H J, Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety-effect of obesity and weight reduction.  Int J Obes Relat Metab Disord. 2001;  25 1206-1214
    CrossrefPubMedGoogle Scholar
  • 41 Naslund E, King N, Mansten S, Adner N, Holst J J, Gutniak M, Hellstrom P M. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects.  Br J Nutr. 2004;  91 439-446
    CrossrefPubMedGoogle Scholar
  • 42 Dakin C L, Small C J, Park A J, Seth A, Ghatei M A, Bloom S R. Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats.  Am J Physiol Endocrinol Metab. 2002;  283 E1173-E1177
    PubMedGoogle Scholar
  • 43 Dakin C L, Small C J, Batterham R L, Neary N M, Cohen M A, Patterson M, Ghatei M A, Bloom S R. Peripheral oxyntomodulin reduces food intake and body weight gain in rats.  Endocrinology. 2004;  145 2687-2695
    CrossrefPubMedGoogle Scholar
  • 44 Tang-Christensen M, Vrang N, Larsen P J. Glucagon-like peptide containing pathways in the regulation of feeding behaviour.  Int J Obes Relat Metab Disord. 2001;  25 Suppl 5 S42-S47
    PubMedGoogle Scholar
  • 45 Fehmann H C, Jiang J, Schweinfurth J, Wheeler M B, Boyd A E, III , Goke B. Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9 - 39).  Peptides. 1994;  15 453-456
    CrossrefPubMedGoogle Scholar
  • 46 Cohen M A, Ellis S M, Le R oux, Batterham R L, Park A, Patterson M, Frost G S, Ghatei M A, Bloom S R. Oxyntomodulin suppresses appetite and reduces food intake in humans.  J Clin Endocrinol Metab. 2003;  88 4696-4701
    CrossrefPubMedGoogle Scholar
  • 47 Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson P A, Sandqvist M, Bavenholm P, Efendic S, Eriksson J W, Dickinson S, Holmes D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.  Diabetes Care. 2002;  25 869-875
    PubMedGoogle Scholar
  • 48 Glover I, Haneef I, Pitts J, Wood S, Moss D, Tickle I, Blundell T. Conformational flexibility in a small globular hormone: x-ray analysis of avian pancreatic polypeptide at 0.98-A resolution.  Biopolymers. 1983;  22 293-304
    CrossrefPubMedGoogle Scholar
  • 49 Eberlein G A, Eysselein V E, Schaeffer M, Layer P, Grandt D, Goebell H, Niebel W, Davis M, Lee T D, Shively J E. A new molecular form of PYY: structural characterization of human PYY(3 - 36) and PYY(1 - 36).  Peptides. 1989;  10 797-803
    CrossrefPubMedGoogle Scholar
  • 50 Larhammar D. Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide.  Regul Pept. 1996;  65 165-174
    CrossrefPubMedGoogle Scholar
  • 51 Adrian T E, Ferri G L, Bacarese-Hamilton A J, Fuessl H S, Polak J M, Bloom S R. Human distribution and release of a putative new gut hormone, peptide YY.  Gastroenterology. 1985;  89 1070-1077
    PubMedGoogle Scholar
  • 52 Lin H C, Chey W Y. Cholecystokinin and peptide YY are released by fat in either proximal or distal small intestine in dogs.  Regul Pept. 2003;  114 131-135
    CrossrefPubMedGoogle Scholar
  • 53 Pedersen-Bjergaard U, Host U, Kelbaek H, Schifter S, Rehfeld J F, Faber J, Christensen N J. Influence of meal composition on postprandial peripheral plasma concentrations of vasoactive peptides in man.  Scand J Clin Lab Invest. 1996;  56 497-503
    CrossrefPubMedGoogle Scholar
  • 54 Fu-Cheng X, Anini Y, Chariot J, Castex N, Galmiche J P, Roze C. Mechanisms of peptide YY release induced by an intraduodenal meal in rats: neural regulation by proximal gut.  Pflugers Arch. 1997;  433 571-579
    PubMedGoogle Scholar
  • 55 Batterham R L, Cowley M A, Small C J, Herzog H, Cohen M A, Dakin C L, Wren A M, Brynes A E, Low M J, Ghatei M A, Cone R D, Bloom S R. Gut hormone PYY(3 - 36) physiologically inhibits food intake.  Nature. 2002;  418 650-654
    CrossrefPubMedGoogle Scholar
  • 56 Challis B G, Pinnock S B, Coll A P, Carter R N, Dickson S L, O’Rahilly S. Acute effects of PYY3 - 36 on food intake and hypothalamic neuropeptide expression in the mouse.  Biochem Biophys Res Commun. 2003;  311 915-919
    CrossrefPubMedGoogle Scholar
  • 57 Halatchev I G, Ellacott K L, Fan W, Cone R D. Peptide YY3 - 36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism.  Endocrinology. 2004;  145 2585-2590
    CrossrefPubMedGoogle Scholar
  • 58 Challis B G, Coll A P, Yeo G S, Pinnock S B, Dickson S L, Thresher R R, Dixon J, Zahn D, Rochford J J, White A, Oliver R L, Millington G, Aparicio S A, Colledge W H, Russ A P, Carlton M B, O’Rahilly S. Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3 - 36).  Proc Natl Acad Sci U S A. 2004;  101 4695-4700
    CrossrefPubMedGoogle Scholar
  • 59 Martin N M, Small C J, Sajedi A, Patterson M, Ghatei M A, Bloom S R. Pre-obese and obese agouti mice are sensitive to the anorectic effects of peptide YY(3 - 36) but resistant to ghrelin.  Int J Obes Relat Metab Disord. 2004;  28 886-893
    CrossrefPubMedGoogle Scholar
  • 60 Cox J E, Randich A. Enhancement of feeding suppression by PYY(3 - 36) in rats with area postrema ablations.  Peptides. 2004;  25 985-989
    CrossrefPubMedGoogle Scholar
  • 61 Pittner R A, Moore C X, Bhavsar S P, Gedulin B R, Smith P A, Jodka C M, Parkes D G, Paterniti J R, Srivastava V P, Young A A. Effects of PYY 3-36 in rodent models of diabetes and obesity.  Int J Obes Relat Metab Disord. 2004;  in press
    PubMedGoogle Scholar
  • 62 Tschop M, Castaneda T R, Joost H G, Thone-Reinke C, Ortmann S, Klaus S, Hagan M M, Chandler P C, Oswald K D, Benoit S C, Seeley R J, Kinzig K P, Moran T H, Beck-Sickinger A G, Koglin N, Rodgers R J, Blundell J E, Ishii Y, Beattie A H, Holch P, Allison D B, Raun K, Madsen K, Wulff B S, Stidsen C E, Birringer M, Kreuzer O J, Schindler M, Arndt K, Rudolf K, Mark M, Deng X Y, Whitcomb D C, Halem H, Taylor J, Dong J, Datta R, Culler M, Craney S, Flora D, Smiley D, Heinman M L. Physiology: does gut hormone PYY3 - 36 decrease food intake in rodents?.  Nature. 2004;  430 (6996) 1p
    PubMedGoogle Scholar
  • 63 De S J, Butler A A, Cone R D. Disproportionate inhibition of feeding in A(y) mice by certain stressors: a cautionary note.  Neuroendocrinology. 2000;  72 126-132
    CrossrefPubMedGoogle Scholar
  • 64 Conrad C D, McEwen B S. Acute stress increases neuropeptide Y mRNA within the arcuate nucleus and hilus of the dentate gyrus.  Brain Res Mol Brain Res. 2000;  79 102-109
    PubMedGoogle Scholar
  • 65 Makino S, Baker R A, Smith M A, Gold P W. Differential regulation of neuropeptide Y mRNA expression in the arcuate nucleus and locus coeruleus by stress and antidepressants.  J Neuroendocrinol. 2000;  12 387-395
    CrossrefPubMedGoogle Scholar
  • 66 Kanatani A, Mashiko S, Murai N, Sugimoto N, Ito J, Fukuroda T, Fukami T, Morin N, MacNeil D J, Van der Ploeg L H, Saga Y, Nishimura S, Ihara M. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice.  Endocrinology. 2000;  141 1011-1016
    CrossrefPubMedGoogle Scholar
  • 67 Batterham R L, Cohen M A, Ellis S M, Le R oux, Withers D J, Frost G S, Ghatei M A, Bloom S R. Inhibition of food intake in obese subjects by peptide YY3 - 36.  N Engl J Med. 2003;  349 941-948
    CrossrefPubMedGoogle Scholar
  • 68 Asakawa A, Inui A, Yuzuriha H, Ueno N, Katsuura G, Fujimiya M, Fujino M A, Niijima A, Meguid M M, Kasuga M. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance.  Gastroenterology. 2003;  124 1325-1336
    CrossrefPubMedGoogle Scholar
  • 69 Ueno N, Inui A, Iwamoto M, Kaga T, Asakawa A, Okita M, Fujimiya M, Nakajima Y, Ohmoto Y, Ohnaka M, Nakaya Y, Miyazaki J I, Kasuga M. Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice.  Gastroenterology. 1999;  117 1427-1432
    PubMedGoogle Scholar
  • 70 Whitcomb D C, Puccio A M, Vigna S R, Taylor I L, Hoffman G E. Distribution of pancreatic polypeptide receptors in the rat brain.  Brain Res. 1997;  760 137-149
    CrossrefPubMedGoogle Scholar
  • 71 Clark J T, Kalra P S, Crowley W R, Kalra S P. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats.  Endocrinology. 1984;  115 427-429
    CrossrefPubMedGoogle Scholar
  • 72 Flynn M C, Turrin N P, Plata-Salaman C R, Ffrench-Mullen J M. Feeding response to neuropeptide Y-related compounds in rats treated with Y5 receptor antisense or sense phosphothio-oligodeoxynucleotide.  Physiol Behav. 1999;  66 881-884
    CrossrefPubMedGoogle Scholar
  • 73 Batterham R L, Le Roux C W, Cohen M A, Park A J, Ellis S M, Patterson M, Frost G S, Ghatei M A, Bloom S R. Pancreatic polypeptide reduces appetite and food intake in humans.  J Clin Endocrinol Metab. 2003;  88 3989-3992
    CrossrefPubMedGoogle Scholar
  • 74 Zipf W B, O’Dorisio T M, Cataland S, Sotos J. Blunted pancreatic polypeptide responses in children with obesity of Prader-Willi syndrome.  J Clin Endocrinol Metab. 1981;  52 1264-1266
    PubMedGoogle Scholar
  • 75 Berntson G G, Zipf W B, O’Dorisio T M, Hoffman J A, Chance R E. Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome.  Peptides. 1993;  14 497-503
    CrossrefPubMedGoogle Scholar
  • 76 Neary N M, Small C J, Park A J, Ellis S M, Filipsson K, Wang F, Dakin C L, Ghatei M A, Bloom S R. Gut hormones peptide YY3 - 36 and glucagon like peptide-1 have an additive physiological role in the inhibition of food intake. Society for Neuroscience meeting, USA 2003: Program No. 231.1
    Google Scholar

Prof. S. R. Bloom

Department of Metabolic Medicine, Imperial College Faculty of Medicine, Hammersmith Hospital

6th Floor Commonwealth Building · Du Cane Road · London · W12 ONN · United Kingdom ·

Phone: + 44 (208) 383 3242

Fax: + 44 (208) 383 3142

Email: s.bloom@imperial.ac.uk